Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Indian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the ca...

Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...

Cipla, a drugmaker involved in supplying HIV medications through US-supported programmes, anticipates minimal impact from the Trump adminis...

Cipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA appr...

Backorders and complaints over low supply started moderating in the second week of May, the drugmaker said, after it began ramping up produ...

"We have scaled up the production of remdesivir by 2x from the last wave of the pandemic," Cipla said in a statement. "Given the unpreceden...

Cipla has been awarded $188.95 million tender for anti-retrovirals drugs by Global Fund which would enable it to supply the medicines to ov...

Boehringer Ingelheim in talks with Cipla for supply of generic drugs to the $17-bn German coa for two drugs.

South African company Adcock Ingram's plans to buy Cipla Medpro, with whom Cipla has a 20-year drug-supply agreement, has run into trouble ...

If the deal is sealed, Cipla will supply generic pharmaceutical products to Reliance Retail.